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MaOBJECTIVES In propensity score–matched patients with severe aortic stenosis treated with surgical aortic valve
replacement (AVR) with the 3f Enable sutureless prosthesis (Medtronic, Minneapolis, Minnesota) or transcatheter aortic
valve replacement (TAVR), the hemodynamic performance of both valves and mid-term survival of patients were
evaluated.
BACKGROUND Data on hemodynamic performance of surgical sutureless bioprostheses in high operative risk patients
with aortic stenosis are scarce.
METHODS Of 258 patients undergoing TAVR or surgical aortic valve replacement with the 3f Enable valve,
80 (79  5 years of age, 100% men) were included in the current analysis on the basis of propensity score 1:1 matching
for baseline clinical and hemodynamic characteristics. All patients had hemodynamic echocardiographic evaluation at
baseline and discharge. Mid-term survival was analyzed.
RESULTS Compared with the 3f Enable valve, TAVR prostheses (Edwards SAPIEN XT [Edwards Lifesciences, Irvine,
California] and CoreValve [Medtronic]) had larger effective oriﬁce area index (1.000.30 cm2/m2 vs. 0.760.22 cm2/m2;
p < 0.001), lower pressure gradient (8.14  4.21 mm Hg vs. 10.72  4.01 mm Hg; p ¼ 0.006), less frequent prosthesis-
patient mismatch (30.0% vs. 67.5%; p ¼ 0.001), and low ﬂow (46.2% vs. 72.5%; p ¼ 0.02), but more frequent aortic
regurgitation (87.5% vs. 20.0%; p < 0.001). The presence of prosthesis-patient mismatch was independently associated
with a low-ﬂow state at discharge (odds ratio: 4.70; p¼0.004) and independently associatedwith the use of the sutureless
prosthesis (odds ratio: 3.90; p¼ 0.02). However, the survival of the 2 groups was comparable after 1.5-year (interquartile
range: 0.79 to 2.01 years) follow-up (log-rank test, p ¼ 0.95).
CONCLUSIONS TAVR prostheses demonstrated better hemodynamics than the 3f Enable valve but a higher incidence of
aortic regurgitation. However, these differences did not inﬂuence mid-term survival of patients. (J Am Coll Cardiol Intv
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671AB BR E V I A T I O N S
AND ACRONYM S
AR = aortic regurgitation
AVR = aortic valve
replacement
CI = conﬁdence interval
OR = odds ratio
PPM = patient-prosthesis
mismatch
SVi = stroke volume index
TAVR = transcatheter aortic
valve replacementI n patients with severe aortic stenosis and highoperative risk, transcatheter aortic valve replace-ment (TAVR) has been shown to be noninferior to
conventional surgical aortic valve replacement (AVR)
when using the balloon-expandable Edwards SAPIEN
valve (Edwards Lifesciences, Irvine, California) and
superior to surgical AVR when using the self-
expandable CoreValve (Medtronic, Minneapolis, Min-
nesota) (1–3). Recently, surgical AVR with sutureless
prostheses offers minimal surgical access, reduced
aortic cross-clamping, and cardiopulmonary bypass
times compared with classic surgical replacement,
and, in contrast to TAVR, the native calciﬁed valve
is removed (4–6). In patients with severe aortic steno-
sis and high operative risk, perioperative complica-
tions and in-hospital mortality associated with
surgical AVR using sutureless valves are comparable
to those with TAVR (4,6,7). Compared with stentless
aortic bioprostheses, TAVR prostheses have demon-
strated superior hemodynamics (8). However, littleFIGURE 1 3f Enable Aortic Root Bioprosthesis
SEE PAGE 678is known about the hemodynamics of sutureless
valves in comparison with TAVR prostheses. In pro-
pensity score–matched populations, the present eval-
uation compared the hemodynamic performance of
the sutureless 3f Enable valve (Medtronic, Minneapo-
lis, Minnesota) (Figure 1) and transcatheter valves
(SAPIEN XT and CoreValve). In addition, the mid-
term survival of patients undergoing surgical suture-
less AVR and patients treated with TAVR was
evaluated.The valve consists of a self-expanding nitinol frame and 3 equine
pericardial leaﬂets that form a tube, preserving the aortic sinuses
and restoring native stress distribution. Reprinted with permission
from Medtronic Inc.METHODS
IDENTIFICATION OF PATIENTS. Patients with symp-
tomatic severe aortic stenosis (aortic valve area
index <0.6 cm2/m2) (9) who were treated according to
the Heart Team (10) with surgical AVR using the 3f
Enable valve or with TAVR at the Leiden University
Medical Centre between November 2007 and February
2013 were evaluated. Only patients with a successful
procedure, deﬁned as no immediate procedural mor-
tality within 72 h post-procedure (11), were considered
eligible for the current analysis. The immediate pro-
cedural mortality rate was 2% for surgical AVR using
the 3f Enable and 4.5% for TAVR. The Institutional
Review Board of the Leiden University Medical Center
approved this retrospective analysis of clinically ac-
quired data and waived the need for written patient
informed consent.
PROSTHESIS SELECTION AND REPLACEMENT. TAVR was
performed according to current recommendations(12). The type of valve, Edwards SAPIEN XT or
CoreValve, the size of valve and implantation
access (transfemoral or transapical) were
selected before the procedure on the basis of
the multidetector row computed tomography
measurements (13).
Surgical sutureless AVR was performed as
recently described (4). The 3f Enable sutureless
bioprosthesis was implanted and deployed after
a medial sternotomy via a transverse aortotomy
and after excision of the native valve and
decalciﬁcation of the aortic annulus (5,14,15).
The size of the valve (19, 21, 23, 25, or 27 mm)
was selected during the procedure, on the basis of aortic
annulus direct observation and measurement with sur-
gical calipers of standard diameter (5).
HEMODYNAMIC ASSESSMENTWITH ECHOCARDIOGRAPHY.
Transthoracic echocardiography was performed at
baseline (pre-AVR) and at hospital discharge. Using
continuous wave Doppler, the peak velocity through
the valve (native and bioprosthesis) and the mean
transvalvular pressure gradient were obtained, and
the aortic valve area of the native valve and the
TABLE 2
Transcath
Maximal t
Mean pres
Effective o
Prosthesis
Doppler v
Prosthesis
AR grade
AR grade
MR grade
Left ventr
Stroke vol
Low ﬂow
Values are m
MR ¼ mit
TABLE 1 Baseline Characteristics Included in the Propensity Score for the Total
and 1:1 Propensity Score–Matched Population
Total Population (N ¼ 258) Propensity Score Matched (n ¼ 80)
Sutureless AVR
(n ¼ 47)
TAVR
(n ¼ 211) p Value
Sutureless AVR
(n ¼ 40)
TAVR
(n ¼ 40) p Value
Age, yrs 78.5  4.6 80.9  7.1 0.03 79  4.5 79  5.9 0.96
Male 47 (100) 105 (50) <0.001 40 (100) 40 (100) 1.00
BSA, m2 1.9  0.36 1.8  0.2 0.17 1.9  0.4 1.9  0.2 0.69
Log EuroSCORE, % 14.9  10.1 22.8  13.2 <0.001 15.9  10.6 15.5  8.4 0.85
LVEF, % 61.2  10.4 54.8  14.5 0.004 59.9  10.5 59.7  10.7 0.93
MPG, mm Hg 43.2  18.1 42.2  17.2 0.74 42.9  18.7 44.7  17.5 0.65
Annulus, cm 2.42  0.2 2.26  0.2 <0.001 2.4  0.2 2.4  0.2 0.68
AVAi, cm2/m2 0.37  0.14 0.39  0.10 0.26 0.38  0.14 0.38  0.09 0.72
SVi, ml/m2 36.3  10.9 37.1  11.5 0.68 35.8  11.0 35.9  10.8 0.96
Low ﬂow 24 (51.1) 102 (48.3) 0.74 21 (52.5) 21 (52.5) 1.00
Values are mean  SD or n (%).
AVAi ¼ aortic valve area index; AVR ¼ aortic valve replacement; BSA ¼ body surface area; LVEF ¼ left
ventricular ejection fraction; MPG ¼ mean pressure gradient; SVi ¼ stroke volume index; TAVR ¼ transcatheter
aortic valve replacement.
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672effective oriﬁce area of the bioprosthesis were
derived with the continuity equation and indexed to
body surface area (9). Moderate and severe
prosthesis-patient mismatch (PPM) was deﬁned by an
estimated effective oriﬁce area index <0.85 cm2/m2
and <0.65 cm2/m2, respectively (16–19). Aortic
regurgitation (AR) and mitral regurgitation were
assessed using color Doppler data and classiﬁed as I
to IV (16). The forward ﬂow through the aortic valve,
native or bioprosthesis, was evaluated by the stroke
volume index (SVi) calculated as the cross-sectional
area of the left ventricular outﬂow tract multiplied
by the velocity time integral of the left ventricularComparison of the Hemodynamic Proﬁle of the Sutureless Versus
eter Aortic Valve Prosthesis at Discharge
Sutureless AVR
(n ¼ 40)
TAVR
(n ¼ 40) p Value
ransaortic velocity, m/s 2.32  0.44 1.88  0.41 <0.001
sure gradient, mm Hg 10.72  4.01 8.14  4.21 0.006
riﬁce area index, cm2/m2 0.76  0.22 1.00  0.30 <0.001
patient mismatch 27 (67.5) 12 (30.0) 0.001
elocity index 0.46  0.11 0.57  0.15 0.001
size/annulus diameter 0.97  0.08 1.12  0.11 <0.001
I 6 (15) 26 (65) <0.001
II 2 (5) 9 (22.5) <0.001
I-II 27 (69.3) 30 (76.9) 0.45
icular ejection fraction, % 63.50  12.63 59.57  10.46 0.15
ume index, ml/m2 29.91  10.47 35.56  12.50 0.03
29 (72.5) 18 (46.2) 0.02
ean  SD or n (%).
ral regurgitation; other abbreviations as in Table 1.outﬂow tract pulsed wave Doppler spectral signal and
divided by the body surface area. Subsequently, the
low-ﬂow state was deﬁned as SVi #35 ml/m2 (20,21).
The ratio of the prosthesis diameter relative to the
aortic annulus diameter, measured on the parasternal
long-axis view, was estimated to assess the grade of
under- or oversizing of the prosthesis (8,22). Left
ventricular ejection fraction was evaluated with
Simpson’s biplane method (22).
CLINICAL OUTCOME. The procedural outcome and
the periprocedural complications were recorded
according to Valve Academic Research Consortium
2 deﬁnitions (11). All patients were followed after sur-
gical AVR or TAVR, and all-cause mortality data were
recorded in the Cardiology Department Information
System (EPD-Vision, Leiden University Medical Cen-
ter, Leiden, the Netherlands) or the Social Security
death index and were complete for all patients
included in this analysis.
STATISTICAL ANALYSIS. To control the selection
bias, propensity score matching was performed. The
propensity score was created from a multivariate
binary logistic regression model in which the type of
procedure (AVR with sutureless valve or TAVR) was
the dependent variable. The covariates in this model
were clinical parameters that had affected our choice
of procedure and the echocardiographic variables that
would affect the hemodynamics of the bioprosthesis:
age, sex, body surface area, logistic EuroSCORE I,
aortic annulus, mean transvalvular pressure gradient,
aortic valve area index, SVi, and left ventricular
ejection fraction at baseline. The Hosmer-Lemeshow
goodness-of-ﬁt test was used to check the accuracy
of the model (p ¼ 0.98). Subsequently, propensity
score 1:1 matching was performed without replace-
ment (23).
Continuous variables are expressed as mean  SD
or as median (interquartile range) if not normally
distributed and categorical variables as frequency
(percent). For comparison of continuous variables,
the Student t test, 1-way analysis of variance (with
Bonferroni post-hoc analysis), or the Mann-Whitney
U test was used, as appropriate. For comparison of
categorical variables, the chi-square or Fisher exact
test was used, as appropriate. Univariate and multi-
variate binary logistic regression analyses were per-
formed to identify variables that were associated
with the low-ﬂow state or PPM after surgical AVR or
TAVR. Variables with a univariate p value <0.10 were
entered in the multivariate models. Odds ratios (ORs)
and 95% conﬁdence intervals (CIs) were reported.
The cumulative survival curves were calculated on
the basis of Kaplan-Meier method, and comparison
FIGURE 2 PPM and AR
Prosthesis-patient mismatch (PPM) was more frequent after surgical sutureless aortic valve replacement (SU-AVR), whereas aortic
regurgitation (AR) was more frequent after transcatheter aortic valve replacement (TAVR).
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673of the surgical AVR and TAVR groups was performed
by log-rank test.
Statistical analysis was performed using the
SPSS software version 20 (SPSS, Chicago, Illinois).
A p value <0.05 deﬁned statistical signiﬁcance.
RESULTS
PATIENTS. Of the 258 patients with severe aortic
stenosis successfully treated with surgical AVR using
the sutureless prosthesis or TAVR, 80 patients were
included in the present analysis after propensity
score 1:1 matching. The baseline clinical andFIGURE 3 Association Between PPM, AR, and Forward Flow After S
(A) Patients treated with surgical SU-AVR and who showed PPM had a
(B) There were no differences in stroke volume between patients with an
variance; SVi ¼ stroke volume index; other abbreviations as in Figure 2.echocardiographic data used for propensity score
matching of the 2 cohorts are shown in Table 1.
AORTIC VALVE HEMODYNAMICS AT DISCHARGE:
TAVR VERSUS SUTURELESS BIOPROSTHESIS. The
hemodynamics of the transcatheter and sutureless
bioprostheses are shown in Table 2. The TAVR group
had a signiﬁcantly lower mean transvalvular pressure
gradient (8.14  4.21 mm Hg vs. 10.72  4.01 mm Hg;
p ¼ 0.006), higher effective oriﬁce area index
(1.00  0.30 cm2 vs. 0.76  0.22 cm2; p < 0.001), less
frequent presence of PPM, higher SVi, and less
frequent presence of a low-ﬂow state, but a higherU-AVR and TAVR
signiﬁcantly lower stroke volume compared with the other groups.
d without signiﬁcant AR after surgical or TAVR. ANOVA ¼ analysis of
TABLE 3 Univariate and Multivariate Binary Logistic Regression Analyses
to Identify Factors That Deﬁne Low-Flow State Post Sutureless and
Transcatheter Aortic Valve Replacement
Univariate Multivariate
OR 95% CI p Value OR 95% CI p Value
Age, yrs 1.06 0.97–1.16 0.18
Sutureless AVR 3.08 1.21–7.85 0.02 1.29 0.23–7.26 0.77
PPM 5.81 2.13–15.83 0.001 4.70 1.64–13.48 0.004
AR 0.42 0.17–1.07 0.07 0.70 0.17–2.85 0.62
Post-LVEF, % 1.04 0.99–1.08 0.12
AVP size/annulus 0.03 0.001–1.55 0.08 0.33 0.002–64.03 0.68
Propensity score 0.69 0.06–8.06 0.77
AVP size/annulus ¼ aortic valve prosthesis size/aortic annulus diameter; CI ¼ conﬁdence interval;
OR ¼ odds ratio; PPM ¼ prosthesis-patient mismatch; other abbreviations as in Tables 1 and 2.
TABLE 4
Identify F
Transcath
Sutureless
Annulus, c
AVP size/a
Propensity
Abbreviatio
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674frequency of AR compared with the patients who
received a sutureless bioprosthesis (Figure 2).
PPM, AORTIC VALVE PROSTHESIS REGURGITATION,
AND FORWARD FLOW AT DISCHARGE: TAVR VERSUS
SUTURELESS BIOPROSTHESIS. The patient popula-
tion was divided into 4 groups on the basis of the type
of prosthesis and the presence of PPM at discharge:
surgical sutureless AVR with PPM, surgical sutureless
AVR with no PPM, TAVR with PPM, and TAVR with no
PPM. The forward ﬂow was signiﬁcantly different
among the 4 groups (SVi: 24.63  7.32 ml/m2 vs. 40.89
 6.86 ml/m2 vs. 30.94  9.15 ml/m2 vs. 37.61  13.36
ml/m2, respectively; analysis of variance, p < 0.001).
Patients treated with sutureless AVR who showed
PPM had a signiﬁcantly lower SVi than patients
without PMM or treated with TAVR (Bonferroni, p <
0.001 for both). Additionally, PPM patients had a
signiﬁcantly lower SVi than the no PPM patients
(38.68  11.66 ml/m2 vs. 26.57  8.35 ml/m2; p <
0.001) (Figure 3A).
Subsequently, the patient population was divided
into 4 groups on the basis of the type of prosthesis and
the presence of AR at discharge: surgical sutureless
AVR with AR, surgical sutureless AVR no AR, TAVR
with AR, and TAVR no AR. The forward ﬂow was notUnivariate and Multivariate Binary Logistic Regression Analyses to
actors That Deﬁne Prosthesis-Patient Mismatch Post-Sutureless and
eter Aortic Valve Replacement
Univariate Multivariate
OR 95% CI p Value OR 95% CI p Value
AVR 4.67 1.81–12.07 0.001 3.90 1.22–12.50 0.02
m 1.37 0.19–9.73 0.76
nnulus 0.01 0.001–0.56 0.03 0.28 0.002–37.61 0.61
score 0.29 0.03–3.37 0.32
ns as in Tables 1 and 2.signiﬁcantly different among these 4 groups (SVi:
29.92  11.83 ml/m2 vs. 29.91  10.32 ml/m2 vs. 35.19 
12.60 ml/m2 vs. 38.11  12.85 ml/m2, respectively;
analysis of variance, p ¼ 0.19). Additionally, patients
with AR at discharge did not have a signiﬁcantly higher
SVi than the patients with no AR (34.18  12.49 ml/m2
vs. 31.02  10.87 ml/m2; p ¼ 0.24) (Figure 3B).
A low-ﬂow state at discharge was present in 79.5%
of the patients with PPM versus 40% of patients
without PPM (p < 0.001). However, a low-ﬂow state
was observed in 70% of patients with AR versus 50%
of patients without AR (p ¼ 0.07). The presence of
PPM was independently associated with a low-ﬂow
state at discharge (OR: 4.70; 95% CI: 1.64 to 13.48;
p ¼ 0.004) (Table 3). Surgical AVR with a sutureless
bioprosthesis was independently associated with
PPM at discharge (OR: 3.90; 95% CI: 1.22 to 12.50;
p ¼ 0.02) (Table 4).
CLINICAL OUTCOME. Although the hemodynamic
characteristics of the TAVR prosthesis were more
favorable compared with the sutureless prosthesis,
the survival during a median follow-up of 1.5 years
(interquartile range: 0.79 to 2.01 years) was compa-
rable in the 2 groups (log-rank test, p ¼ 0.95)
(Figure 4). The 2-year survival rate for patients
treated with a sutureless bioprosthesis was 92.5%
compared with 87.3% for patients undergoing TAVR.
The periprocedural complications were comparable in
the 2 groups, although there was a trend toward more
vascular complications in the TAVR group and more
bleeding complications in the surgical sutureless
group (Table 5).
DISCUSSION
The present study demonstrated that transcatheter
bioprostheses have a better hemodynamic proﬁle
than the surgical sutureless 3f Enable valve in terms
of effective oriﬁce area index, mean transvalvular
pressure gradient, and PPM. However, AR was pre-
sent more often after TAVR. The sutureless bio-
prosthesis was independently associated with PPM at
discharge. Although the 2 types of valves have sig-
niﬁcant differences in hemodynamic performance at
discharge, the mid-term survival of the patients was
comparable.
HEMODYNAMICS OF TRANSCATHETER AND SUTURELESS
AORTIC BIOPROSTHESES. The improved hemodynam-
ics of transcatheter aortic bioprostheses compared
with stentless or stented surgical aortic biopros-
theses have been demonstrated (8,24). Clavel et al.
(8) reported a larger effective oriﬁce area index
FIGURE 4 Survival Analysis
Kaplan-Meier estimates of time to death in patients treated with
TAVR and patients treated with SU-AVR using the sutureless
Medtronic 3f Enable valve. Abbreviations as in Figure 2.
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675(0.90  0.26 cm2/m2), lower mean pressure gradient
(10  4 mm Hg), and a lower percent of severe PPM
(11%) in transcatheter aortic bioprostheses compared
with stentless (0.80  0.21 cm2/m2, 14  6 mm Hg,
and 28%, respectively) and stented (0.76  0.16
cm2/m2, 13  5 mm Hg, and 26%, respectively) bio-
prostheses. However, the presence of AR grade I or
higher after TAVR was more frequently observed
compared with surgical AVR using stentless orTABLE 5 Periprocedural Complications on the Basis of Valve
Academic Research Consortium 2 Deﬁnitions
Sutureless AVR
(n ¼ 40)
TAVR
(n ¼ 40) p Value
Cerebrovascular accident 0.31
Stroke 2 (5) 1 (2.5)
Transient ischemic attack 1 (2.5) 0
Bleeding 0.07
Minor 4 (10) 1 (2.5)
Major 3 (7.5) 0
Conduction disturbances 0.69
Transient complete AV block 3 (7.5) 0
Pacemaker implantation 1 (2.5) 3 (7.5)
Acute kidney injury 0.28
Stage 1 5 (12.5) 6 (15)
Stage 2 0 2 (5)
Vascular injury 0.08
Major 0 0
Minor 0 3 (7.5)
Values are n (%).
AV ¼ atrioventricular; other abbreviations as in Table 1.stented bioprostheses (50% vs. 12% and 10%,
respectively) (8).
Few studies have compared the hemodynamics of
transcatheter aortic bioprostheses and surgical
sutureless bioprostheses (7,25). In 37 patients, San-
tarpino et al. (7) reported comparable mean pres-
sure gradients in transcatheter and sutureless
bioprostheses (14.2  5.8 mm Hg vs. 13.3  3.9 mm Hg,
respectively) and a higher incidence of AR
among patients undergoing TAVR (13.5% vs. 0%,
respectively). The present study conﬁrms previous
results and provides additional data in terms of the
incidence of PPM, which was lower in patients treated
with transcatheter aortic bioprostheses compared
with patients receiving a sutureless bioprosthesis.
PPM was independently associated with forward
low-ﬂow status, which was more prevalent among
patients receiving a sutureless bioprosthesis. Addi-
tionally, in TAVR, the prevalence of a low-ﬂow status
was low despite having a higher incidence of AR
compared with a sutureless bioprosthesis. These
ﬁndings are in agreement with those of the substudy
of the PARTNER (Placement of Aortic Transcatheter
Valve) trial showing no association with low-ﬂow
status after TAVR with AR (24).
More importantly, current results were reported in
a propensity score–matched population on the basis
of baseline clinical, hemodynamic, and anatomic pa-
rameters that are known to inﬂuence hemodynamics
and survival. This would have resulted in similar
aortic bioprosthesis hemodynamics. However, the
observed higher incidence of PPM after sutureless
AVR could be explained by relative prosthesis
undersizing compared with TAVR bioprostheses
(prosthesis size/annulus diameter ratio was 0.97 
0.08 vs. 1.12  0.11, respectively; p < 0.001). Although
cardiac multidetector row computed tomography was
used to select the TAVR bioprosthesis size and
generally the selected prosthesis is oversized by 10%
to 15% to minimize paravalvular AR (13,26), sizing of
the sutureless bioprosthesis was performed in the
operating theater by using the pre-sized calipers,
which may lead to a smaller prosthesis size and
effective oriﬁce area (5). AR after surgical AVR
with sutureless bioprostheses was less frequent,
perhaps because of the decalciﬁcation of the aortic
annulus performed during the procedure (5,14,15),
whereas after TAVR, the annular calcium may lead
to gaps between the bioprostheses and the native
aortic annulus from which the paravalvular AR may
arise (2).
IMPACT OF HEMODYNAMIC OUTCOME ON SURVIVAL.
The presence of residual AR, low-ﬂow state, and PPM
PERSPECTIVES
WHAT IS KNOWN? Surgical aortic valve replace-
ment using sutureless valves and TAVR are feasible
options for high operative risk patients with severe
aortic stenosis.
WHAT IS NEW? The present evaluation showed
that TAVR prostheses compared with the sutureless
3f Enable prosthesis have a better hemodynamic
proﬁle in terms of a higher effective oriﬁce area
index, a lower mean transvalvular pressure gradient,
and a lower prevalence of forward low ﬂow and
patient prosthesis mismatch. However, TAVR is
associated with a higher incidence of paravalvular
aortic regurgitation.
WHAT IS NEXT? These differences did not affect
mid-term survival; however, further and larger scale
studies should be conducted to clarify this issue.
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676has been associated with the prognosis of patients
undergoing TAVR or surgical AVR for aortic ste-
nosis (24). In several registries and the randomized
PARTNER trial, AR grade I or higher after TAVR has
been associated with a poor outcome (2,27–29).
However, AR was not a predictor of outcome in pa-
tients treated with surgical AVR (24). In contrast, a
low-ﬂow state at follow-up was associated with a
poor prognosis after surgical AVR but not after TAVR
(24). Furthermore, the association between PPM and
survival after TAVR or surgical AVR remains contro-
versial (19,24,30). Ewe et al. (19) and Chacko et al. (30)
suggested that PPM was not associated with survival
after TAVR or surgical AVR, whereas Hahn et al. (24)
concluded that PPM was a predictor of mortality af-
ter both TAVR and surgical AVR.
Studies comparing the impact of the hemody-
namics of transcatheter and sutureless bioprostheses
on survival are scarce. Santarpino et al. (7) reported
better survival after surgical AVR with a sutureless
bioprosthesis compared with TAVR, and the only
difference between the patient groups was the
higher incidence of AR after TAVR compared with
surgical sutureless AVR. The present analysis
showed comparable survival in patients treated
with TAVR and those treated with surgical AVR
using a sutureless bioprosthesis. The low number
of patients and the propensity score–matching pro-
cess may have reduced the power of the study to
observe signiﬁcant differences in survival, prevent-
ing us from investigating the variables indepen-
dently associated with survival.
STUDY LIMITATIONS. The main limitation is the
limited number of patients included in the analysis.
However, the 2 groups of 40 patients were 1:1 pro-
pensity score matched. The inclusion of only men is
another limitation because the results of the present
study may not be applicable to female patients with
smaller body surface areas and aortic annulus.
Moreover, systematic echocardiographic follow-up
data after discharge were not available for patients
treated with a sutureless bioprosthesis. Additionally,
the limited number of patients in each group matched
for hemodynamic parameters mainly may bias the
survival analysis, and a Cox regression analysis was
not performed to explore the independent impact of
bioprosthesis hemodynamics on survival due to thevery few events (n ¼ 13) during the median follow-up
of 1.5 years.
CONCLUSIONS
In high operative risk patients with severe aortic
stenosis treated with valve replacement, TAVR pros-
theses have a better hemodynamic proﬁle at
discharge in terms of a higher effective oriﬁce area
index, lower mean transvalvular pressure gradient,
lower prevalence of forward low-ﬂow, and PPM
compared with those treated with the sutureless 3f
Enable valve. However, the incidence of AR is
signiﬁcantly higher in patients treated with TAVR
than in patients receiving a sutureless bioprosthesis.
Nevertheless, these differences did not have prog-
nostic implications because patients treated with a
sutureless bioprosthesis had mid-term survival com-
parable to those treated with TAVR.
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